$HAE Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in HAEMONETICS CORP.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in HAEMONETICS CORP. Get notifications about new insider transactions in HAEMONETICS CORP for free.
Page: < prev 1 2 3 4 5 6 7 ... 16 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 27 2018 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 92.17 | 5,717 | 526,936 | 15,574 | 21.3 K to 15.6 K (-26.85 %) |
Jun 27 2018 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Buy | M | 41.64 | 5,717 | 238,056 | 21,291 | 15.6 K to 21.3 K (+36.71 %) |
Jun 13 2018 | HAE | HAEMONETICS CORP | Bolorforosh Said | EVP, Chief Technolo ... | Option Exercise | A | 93.52 | 3,330 | 311,422 | 3,330 | |
Jun 13 2018 | HAE | HAEMONETICS CORP | Bolorforosh Said | EVP, Chief Technolo ... | Grant | A | 0.00 | 935 | 0 | 935 | 0 to 935 |
Jun 13 2018 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Option Exercise | A | 93.52 | 1,903 | 177,969 | 1,903 | |
Jun 13 2018 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Grant | A | 0.00 | 534 | 0 | 3,556 | 3 K to 3.6 K (+17.67 %) |
Jun 13 2018 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Option Exercise | A | 93.52 | 5,233 | 489,390 | 5,233 | |
Jun 13 2018 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Grant | A | 0.00 | 1,470 | 0 | 6,253 | 4.8 K to 6.3 K (+30.73 %) |
Jun 13 2018 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Option Exercise | A | 93.52 | 9,516 | 889,936 | 9,516 | |
Jun 13 2018 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Grant | A | 0.00 | 2,673 | 0 | 13,270 | 10.6 K to 13.3 K (+25.22 %) |
Jun 13 2018 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Option Exercise | A | 93.52 | 9,278 | 867,679 | 9,278 | |
Jun 13 2018 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Grant | A | 0.00 | 2,606 | 0 | 15,574 | 13 K to 15.6 K (+20.10 %) |
Jun 13 2018 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Option Exercise | A | 93.52 | 40,443 | 3,782,229 | 40,443 | |
Jun 13 2018 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Grant | A | 0.00 | 11,361 | 0 | 138,265 | 126.9 K to 138.3 K (+8.95 %) |
Jun 12 2018 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 92.90 | 578 | 53,696 | 3,022 | 3.6 K to 3 K (-16.06 %) |
Jun 08 2018 | HAE | HAEMONETICS CORP | Ryding Neil Mr. | EVP, Global Manufac ... | Sell | S | 92.73 | 183 | 16,970 | 15,226 | 15.4 K to 15.2 K (-1.19 %) |
Jun 08 2018 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 92.73 | 425 | 39,410 | 12,968 | 13.4 K to 13 K (-3.17 %) |
Jun 08 2018 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Sell | S | 92.73 | 214 | 19,844 | 4,783 | 5 K to 4.8 K (-4.28 %) |
Jun 08 2018 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Sell | S | 92.73 | 457 | 42,378 | 10,597 | 11.1 K to 10.6 K (-4.13 %) |
Jun 08 2018 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Sell | S | 92.73 | 1,941 | 179,989 | 126,904 | 128.8 K to 126.9 K (-1.51 %) |
Jun 08 2018 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Option Exercise | M | 41.64 | 1,106 | 46,054 | 3,320 | |
Jun 08 2018 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Option Exercise | M | 34.42 | 2,607 | 89,733 | 5,214 | |
Jun 08 2018 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 92.73 | 81 | 7,511 | 3,600 | 3.7 K to 3.6 K (-2.20 %) |
Jun 08 2018 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 95.14 | 1,106 | 105,225 | 3,681 | 4.8 K to 3.7 K (-23.10 %) |
Jun 08 2018 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 95.14 | 2,607 | 248,030 | 4,787 | 7.4 K to 4.8 K (-35.26 %) |
Jun 08 2018 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Buy | M | 41.64 | 1,106 | 46,054 | 7,394 | 6.3 K to 7.4 K (+17.59 %) |
Jun 08 2018 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Buy | M | 34.42 | 2,607 | 89,733 | 6,288 | 3.7 K to 6.3 K (+70.82 %) |
May 23 2018 | HAE | HAEMONETICS CORP | Ryding Neil Mr. | EVP, Global Manufac ... | Sell | S | 46.76 | 267 | 12,485 | 15,409 | 15.7 K to 15.4 K (-1.70 %) |
May 23 2018 | HAE | HAEMONETICS CORP | Ryding Neil Mr. | EVP, Global Manufac ... | Sell | S | 45.70 | 346 | 15,812 | 15,676 | 16 K to 15.7 K (-2.16 %) |
May 23 2018 | HAE | HAEMONETICS CORP | Ryding Neil Mr. | EVP, Global Manufac ... | Payment of Exercise | F | 40.32 | 3,303 | 133,177 | 16,022 | 19.3 K to 16 K (-17.09 %) |
May 23 2018 | HAE | HAEMONETICS CORP | Ryding Neil Mr. | EVP, Global Manufac ... | Sell | S | 34.16 | 351 | 11,990 | 19,325 | 19.7 K to 19.3 K (-1.78 %) |
May 23 2018 | HAE | HAEMONETICS CORP | Burke William P. Mr. | EVP, Chief Financia ... | Sell | S | 46.76 | 841 | 39,325 | 13,393 | 14.2 K to 13.4 K (-5.91 %) |
May 23 2018 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Sell | S | 40.39 | 3,595 | 145,202 | 128,845 | 132.4 K to 128.8 K (-2.71 %) |
Apr 10 2018 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 72.19 | 210 | 15,160 | 3,681 | 3.9 K to 3.7 K (-5.40 %) |
Apr 10 2018 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 46.76 | 111 | 5,190 | 3,891 | 4 K to 3.9 K (-2.77 %) |
Apr 10 2018 | HAE | HAEMONETICS CORP | Goldstein Dan | VP, Corporate Contr ... | Sell | S | 40.39 | 197 | 7,957 | 4,002 | 4.2 K to 4 K (-4.69 %) |
Mar 08 2018 | HAE | HAEMONETICS CORP | Scanlan Jacqueline | SVP, Global Human R ... | Sell | S | 72.23 | 114 | 8,234 | 4,524 | 4.6 K to 4.5 K (-2.46 %) |
Mar 08 2018 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Sell | S | 72.23 | 389 | 28,097 | 10,786 | 11.2 K to 10.8 K (-3.48 %) |
Jan 26 2018 | HAE | HAEMONETICS CORP | Zane Ellen M | Director | Grant | A | 65.86 | 1,301 | 85,684 | 1,301 | 0 to 1.3 K |
Jan 03 2018 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Option Exercise | M | 34.41 | 7,118 | 244,895 | 0 | |
Jan 03 2018 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 63.00 | 7,118 | 448,434 | 26,763 | 33.9 K to 26.8 K (-21.01 %) |
Jan 03 2018 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Buy | M | 34.41 | 7,118 | 244,895 | 33,881 | 26.8 K to 33.9 K (+26.60 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Option Exercise | M | 34.41 | 7,118 | 244,895 | 0 | |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Sell | S | 57.10 | 40 | 2,284 | 32,381 | 32.4 K to 32.4 K (-0.12 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Sell | S | 57.09 | 200 | 11,418 | 32,421 | 32.6 K to 32.4 K (-0.61 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Sell | S | 57.08 | 200 | 11,416 | 32,621 | 32.8 K to 32.6 K (-0.61 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Sell | S | 57.07 | 100 | 5,707 | 32,821 | 32.9 K to 32.8 K (-0.30 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Sell | S | 57.07 | 760 | 43,373 | 32,921 | 33.7 K to 32.9 K (-2.26 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Sell | S | 57.06 | 200 | 11,412 | 33,681 | 33.9 K to 33.7 K (-0.59 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Sell | S | 57.06 | 4,100 | 233,926 | 33,881 | 38 K to 33.9 K (-10.79 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Sell | S | 57.05 | 9 | 513 | 37,981 | 38 K to 38 K (-0.02 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Sell | S | 57.03 | 100 | 5,703 | 37,990 | 38.1 K to 38 K (-0.26 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Sell | S | 57.02 | 91 | 5,189 | 38,090 | 38.2 K to 38.1 K (-0.24 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Sell | S | 57.02 | 100 | 5,702 | 38,181 | 38.3 K to 38.2 K (-0.26 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Sell | S | 57.01 | 100 | 5,701 | 38,281 | 38.4 K to 38.3 K (-0.26 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Sell | S | 57.01 | 100 | 5,701 | 38,381 | 38.5 K to 38.4 K (-0.26 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Sell | S | 57.00 | 300 | 17,100 | 38,481 | 38.8 K to 38.5 K (-0.77 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Buy | M | 34.41 | 7,118 | 244,895 | 38,781 | 31.7 K to 38.8 K (+22.48 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Sell | S | 57.13 | 100 | 5,713 | 32,281 | 32.4 K to 32.3 K (-0.31 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Sell | S | 57.13 | 100 | 5,713 | 32,181 | 32.3 K to 32.2 K (-0.31 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Sell | S | 57.14 | 100 | 5,714 | 32,081 | 32.2 K to 32.1 K (-0.31 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Sell | S | 57.15 | 100 | 5,715 | 31,981 | 32.1 K to 32 K (-0.31 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Sell | S | 57.17 | 200 | 11,434 | 31,781 | 32 K to 31.8 K (-0.63 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Sell | S | 57.18 | 18 | 1,029 | 31,763 | 31.8 K to 31.8 K (-0.06 %) |
Dec 04 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Sell | S | 57.23 | 100 | 5,723 | 31,663 | 31.8 K to 31.7 K (-0.31 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Option Exercise | M | 34.41 | 1,678 | 57,732 | 0 | |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Option Exercise | M | 34.41 | 5,440 | 187,163 | 1,678 | |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Buy | M | 34.41 | 1,678 | 57,732 | 55,695 | 54 K to 55.7 K (+3.11 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.80 | 300 | 17,040 | 54,017 | 54.3 K to 54 K (-0.55 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.78 | 200 | 11,356 | 54,317 | 54.5 K to 54.3 K (-0.37 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.77 | 300 | 17,031 | 54,517 | 54.8 K to 54.5 K (-0.55 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.74 | 300 | 17,021 | 54,817 | 55.1 K to 54.8 K (-0.54 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.73 | 400 | 22,692 | 55,117 | 55.5 K to 55.1 K (-0.72 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.72 | 100 | 5,672 | 55,517 | 55.6 K to 55.5 K (-0.18 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.71 | 100 | 5,671 | 55,617 | 55.7 K to 55.6 K (-0.18 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.70 | 1,200 | 68,040 | 55,717 | 56.9 K to 55.7 K (-2.11 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.69 | 400 | 22,676 | 56,917 | 57.3 K to 56.9 K (-0.70 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.68 | 300 | 17,004 | 57,317 | 57.6 K to 57.3 K (-0.52 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.67 | 300 | 17,001 | 57,617 | 57.9 K to 57.6 K (-0.52 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.67 | 100 | 5,667 | 57,917 | 58 K to 57.9 K (-0.17 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.66 | 100 | 5,666 | 58,017 | 58.1 K to 58 K (-0.17 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.65 | 400 | 22,660 | 58,117 | 58.5 K to 58.1 K (-0.68 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.63 | 200 | 11,326 | 58,517 | 58.7 K to 58.5 K (-0.34 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.62 | 240 | 13,589 | 58,717 | 59 K to 58.7 K (-0.41 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.60 | 200 | 11,320 | 58,957 | 59.2 K to 59 K (-0.34 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.58 | 235 | 13,296 | 59,157 | 59.4 K to 59.2 K (-0.40 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.57 | 65 | 3,677 | 59,392 | 59.5 K to 59.4 K (-0.11 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Buy | M | 34.41 | 5,440 | 187,163 | 59,457 | 54 K to 59.5 K (+10.07 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Option Exercise | M | 34.21 | 11,231 | 384,213 | 33,695 | |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.34 | 162 | 8,803 | 14,034 | 14.2 K to 14 K (-1.14 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.33 | 100 | 5,433 | 14,196 | 14.3 K to 14.2 K (-0.70 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.31 | 200 | 10,862 | 14,296 | 14.5 K to 14.3 K (-1.38 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.29 | 200 | 10,858 | 14,496 | 14.7 K to 14.5 K (-1.36 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.28 | 100 | 5,428 | 14,696 | 14.8 K to 14.7 K (-0.68 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.23 | 100 | 5,423 | 14,796 | 14.9 K to 14.8 K (-0.67 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.21 | 161 | 8,728 | 14,896 | 15.1 K to 14.9 K (-1.07 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.20 | 39 | 2,114 | 15,057 | 15.1 K to 15.1 K (-0.26 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.19 | 100 | 5,419 | 15,096 | 15.2 K to 15.1 K (-0.66 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.17 | 100 | 5,417 | 15,196 | 15.3 K to 15.2 K (-0.65 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.16 | 100 | 5,416 | 15,296 | 15.4 K to 15.3 K (-0.65 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.15 | 200 | 10,830 | 15,396 | 15.6 K to 15.4 K (-1.28 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.29 | 200 | 10,858 | 15,596 | 15.8 K to 15.6 K (-1.27 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.10 | 200 | 10,820 | 15,796 | 16 K to 15.8 K (-1.25 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.04 | 100 | 5,404 | 15,996 | 16.1 K to 16 K (-0.62 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.03 | 100 | 5,403 | 16,096 | 16.2 K to 16.1 K (-0.62 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.01 | 1,122 | 60,599 | 16,196 | 17.3 K to 16.2 K (-6.48 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.00 | 9,909 | 535,086 | 17,318 | 27.2 K to 17.3 K (-36.39 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Buy | M | 34.21 | 11,231 | 384,213 | 27,227 | 16 K to 27.2 K (+70.21 %) |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Option Exercise | M | 34.21 | 1,456 | 49,810 | 4,370 | |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Option Exercise | M | 34.42 | 2,607 | 89,733 | 7,821 | |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Option Exercise | A | 41.64 | 4,426 | 184,299 | 4,426 | |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Option Exercise | A | 34.21 | 5,826 | 199,307 | 5,826 | |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Sell | S | 54.89 | 68 | 3,732 | 4,199 | 4.3 K to 4.2 K (-1.59 %) |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Sell | S | 54.84 | 560 | 30,711 | 4,267 | 4.8 K to 4.3 K (-11.60 %) |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Sell | S | 54.96 | 956 | 52,539 | 4,827 | 5.8 K to 4.8 K (-16.53 %) |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Sell | S | 54.94 | 200 | 10,988 | 5,783 | 6 K to 5.8 K (-3.34 %) |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Sell | S | 54.92 | 300 | 16,476 | 5,983 | 6.3 K to 6 K (-4.77 %) |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Sell | S | 54.95 | 2,607 | 143,242 | 6,283 | 8.9 K to 6.3 K (-29.33 %) |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Buy | M | 34.21 | 1,456 | 49,810 | 8,890 | 7.4 K to 8.9 K (+19.59 %) |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Buy | M | 34.42 | 2,607 | 89,733 | 7,434 | 4.8 K to 7.4 K (+54.01 %) |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Grant | A | 0.00 | 1,080 | 0 | 4,827 | 3.7 K to 4.8 K (+28.82 %) |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Grant | A | 0.00 | 1,350 | 0 | 3,747 | 2.4 K to 3.7 K (+56.32 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Option Exercise | M | 35.50 | 10,353 | 367,557 | 0 | |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Option Exercise | M | 45.45 | 6,573 | 298,743 | 0 | |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.47 | 100 | 5,447 | 20,740 | 20.8 K to 20.7 K (-0.48 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.46 | 200 | 10,892 | 20,840 | 21 K to 20.8 K (-0.95 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.45 | 100 | 5,445 | 21,040 | 21.1 K to 21 K (-0.47 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.40 | 100 | 5,440 | 21,140 | 21.2 K to 21.1 K (-0.47 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.39 | 100 | 5,439 | 21,240 | 21.3 K to 21.2 K (-0.47 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.37 | 200 | 10,874 | 21,340 | 21.5 K to 21.3 K (-0.93 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.26 | 100 | 5,426 | 21,540 | 21.6 K to 21.5 K (-0.46 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.25 | 2,953 | 160,200 | 21,640 | 24.6 K to 21.6 K (-12.01 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.24 | 400 | 21,696 | 24,593 | 25 K to 24.6 K (-1.60 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.23 | 500 | 27,115 | 24,993 | 25.5 K to 25 K (-1.96 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.22 | 2,500 | 135,550 | 25,493 | 28 K to 25.5 K (-8.93 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.21 | 200 | 10,842 | 27,993 | 28.2 K to 28 K (-0.71 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.20 | 100 | 5,420 | 28,193 | 28.3 K to 28.2 K (-0.35 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.19 | 600 | 32,514 | 28,293 | 28.9 K to 28.3 K (-2.08 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.18 | 1,061 | 57,485 | 28,893 | 30 K to 28.9 K (-3.54 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.17 | 1,039 | 56,283 | 29,954 | 31 K to 30 K (-3.35 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.16 | 100 | 5,416 | 30,993 | 31.1 K to 31 K (-0.32 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Buy | M | 35.50 | 10,353 | 367,557 | 31,093 | 20.7 K to 31.1 K (+49.92 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.17 | 1,900 | 102,923 | 20,740 | 22.6 K to 20.7 K (-8.39 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.16 | 100 | 5,416 | 22,640 | 22.7 K to 22.6 K (-0.44 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.15 | 573 | 31,028 | 22,740 | 23.3 K to 22.7 K (-2.46 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.14 | 200 | 10,828 | 23,313 | 23.5 K to 23.3 K (-0.85 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.13 | 600 | 32,478 | 23,513 | 24.1 K to 23.5 K (-2.49 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.12 | 600 | 32,472 | 24,113 | 24.7 K to 24.1 K (-2.43 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.11 | 1,200 | 64,932 | 24,713 | 25.9 K to 24.7 K (-4.63 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.10 | 510 | 27,591 | 25,913 | 26.4 K to 25.9 K (-1.93 %) |